I've just got started with this blog. Give it time and I hope to create a really helpful resource for everyone out there sitting the exam. Please feel free to e-mail suggestions and 'killer' revision notes. Thanks. I would love to hear from you about this blog. Please post a comment.

A little disclaimer: I am doing this blog to hopefully help you when revising due to the very little available information about this exam. I am not affiliated with any organisation in doing this, completely unfunded and not being sponsored. I can not guarantee the accuracy of the information, but will do my best. If you think something is incorrect please let me know so we can all learn. Thanks

Monday, 30 May 2011



Overall View

1.      Identify Molecular Target
-        Involved in cancer growth/development
-        Promise ‘Lead’
2.      Find/Screen/Design a product to interact with target (inhibitor/activator)
3.      Optimisation and Formulation
4.      Pre-clinical studies
-        ‘proof of principle’
-        Animal models for proof of concept and safety data 
5.      Clinical Studies  Phase 1 à 4

e.g. Imatinib (Gleevec)
-        Identify Target: Chromosome Transolcation t(9,22), BCR-ABL fusion protein
-        Lead Compound was found to have Kinase Inhibition, from screening of high throughput screening
-        Optimisation to enhance bioavailability and target specificity
-        Pre-clinical testing demonstrated proof of principle
-        Phase I  to III trials

Screening for Useful Compounds
  •       High Throughput –millions of compounds (libraries) exposed to cell cultures and levels of apoptosis measured
  •      Cominatorial Chemistry- synthetic molecules created
  •            Natural products
  •      ‘In-silico’ approach – virtual computer screening, selecting compounds binding based on knowledge of target structure

No comments: